JPMorgan lowered the firm’s price target on TG Therapeutics to $22 from $23 and keeps an Overweight rating on the shares. The analyst cites balance sheet adjustments for the target drop.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TGTX:
- TG Therapeutics price target raised to $39 from $37.50 at Ladenburg
- Biotech Alert: Searches spiking for these stocks today
- TG Therapeutics price target raised to $45 from $41 at H.C. Wainwright
- Unusually active option classes on open January 10th
- TG Therapeutics (NASDAQ:TGTX) Surges after Preliminary Q4 and FY23 Results
